Research Study

A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
Principal Investigator 
Sean Virani

Overview

Body Locations and Systems 
Heart Failure
ClinicalTrials.gov# 
NCT03057951
Status 
Recruiting
Study Start/End 
Jul 25, 2017 to Dec 30, 2022
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Naomi Uchida/Research Coordinator
Phone 
604-875-4521
Email Address 
naomi.uchida@ubc.ca
Purpose of Study 

The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction

Eligibility 

See Clinicaltrials.gov

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.